Baclofen is NOT Recommended for Migraine Prevention
Baclofen is not a guideline-recommended medication for migraine prevention and should not be used as a first-line, second-line, or third-line agent. The FDA-approved indication for baclofen is limited to spasticity from multiple sclerosis and spinal cord conditions—not migraine 1.
Why Baclofen Is Not Recommended
Absence from Evidence-Based Guidelines
Multiple authoritative guidelines spanning over two decades consistently omit baclofen from their recommendations:
2002 Annals of Internal Medicine guidelines specify first-line preventive agents as propranolol (80-240 mg/d), timolol (20-30 mg/d), amitriptyline (30-150 mg/d), divalproex sodium (500-1500 mg/d), and sodium valproate (800-1500 mg/d) 2. Baclofen is never mentioned.
2021 Nature Reviews Neurology guidelines recommend beta-blockers, topiramate, and candesartan as first-line; flunarizine, amitriptyline, and valproate as second-line; and CGRP monoclonal antibodies as third-line 3. Again, no mention of baclofen.
2024 VA/DoD guidelines and 2025 American College of Physicians guidelines provide extensive recommendations for migraine prevention, including newer agents like CGRP antagonists, but baclofen is completely absent 4, 5.
Limited and Low-Quality Evidence
The only evidence for baclofen in migraine consists of:
One open-label pilot study from 1999 with 54 patients, no placebo control, and high risk of bias 6. While it reported 86.2% of patients had ≥50% headache reduction with baclofen 15-40 mg daily in three divided doses, this single uncontrolled study is insufficient to establish efficacy.
One 2003 narrative review that merely mentions the existence of "two open trials" supporting baclofen but provides no robust evidence 7.
This stands in stark contrast to recommended agents that have multiple high-quality randomized controlled trials demonstrating efficacy.
What You Should Use Instead
For Episodic Migraine Prevention
Start with these first-line agents 2, 3, 4, 5:
- Beta-blockers: Propranolol 80-240 mg/d, metoprolol, or atenolol
- Topiramate: Start low (25 mg) and titrate to 50-200 mg/d
- Candesartan: 16-32 mg/d
- Amitriptyline 30-150 mg/d
- Flunarizine 10 mg/d (where available)
- Valproate 500-1500 mg/d (contraindicated in women of childbearing potential)
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)
- Atogepant (oral CGRP antagonist)
For Chronic Migraine Prevention
OnabotulinumtoxinA injections are specifically indicated for chronic migraine (≥15 headache days/month) 5.
Clinical Algorithm
Assess indication for prevention: ≥2 attacks/month causing ≥3 days disability, contraindication to acute treatment, or overuse of acute medications 2, 4
Choose based on comorbidities:
- Hypertension → Candesartan or beta-blocker
- Depression/insomnia → Amitriptyline
- Obesity → Topiramate
- Multiple failed preventives → CGRP antibodies
Start low, titrate slowly over 2-3 months to assess efficacy 2, 4
Switch if inadequate response after adequate trial (2-3 months) 4
Important Caveats
- Baclofen carries CNS depression risks including sedation, and requires caution with alcohol and other CNS depressants 1
- No established dosing for migraine exists in the literature
- Medication overuse headache is a risk with any frequent acute treatment; preventive therapy addresses this 8, 4
- In women of childbearing potential, avoid valproate and discuss pregnancy risks with all medications 8, 4
Bottom line: Use evidence-based preventive medications with proven efficacy in multiple high-quality trials. Baclofen lacks the evidence base to justify its use when superior alternatives with established safety and efficacy profiles are available.